Advertisement

Topics

Cytotoxic drugs - Biotech, Pharma and Life Science Channel

05:06 EDT 18th August 2017 | BioPortfolio

PubMed Articles [5699 Associated PubMed Articles listed on BioPortfolio]

Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects.

Fullerene C60 as a representative of carbon nanocompounds is suggested to be promising agent for application in photodynamic therapy due to its unique physicochemical properties. The goal of this stud...

Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain.

With the aim to discover new STAT3 direct inhibitors, potentially useful as anticancer agents, a set of methanethiosulfonate drug hybrids were synthesized. The in vitro tests showed that all the thios...

Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.

Four series of pyridothienopyrimidin-4-one derivatives were designed and prepared to improve the pim-1 inhibitory activity of the previously reported thieno[2,3-b]pyridines. Significant improvement in...

Biosynthesis, Characterization, and Bioactivities Evaluation of Silver and Gold Nanoparticles Mediated by the Roots of Chinese Herbal Angelica pubescens Maxim.

A facile synthesis and biological applications of silver (DH-AgNps) and gold nanoparticles (DH-AuNps) mediated by the aqueous extract of Angelicae Pubescentis Radix (Du Huo) are explored. Du Huo is a ...

Non-invasive Photodynamic Therapy in Brain Cancer by Use of Tb(3+)-Doped LaF3 Nanoparticles in Combination with Photosensitizer Through X-ray Irradiation: A Proof-of-Concept Study.

The use of photodynamic therapy (PDT) in the treatment of brain cancer has produced exciting results in clinical trials over the past decade. PDT is based on the concept that a photosensitizer exposed...

Erratum to: Aldo-ketoreductase 1 (AKR1) improves seed longevity in tobacco and rice by detoxifying reactive cytotoxic compounds generated during ageing.

Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?

Photodynamic molecules represent an alternative approach for cancer therapy for their property (i) to be photo-reactive; (ii) to be not-toxic for target cells in absence of light; (iii) to accumulate ...

Molecular targets of dietary phytochemicals for possible prevention and therapy of uterine fibroids: Focus on fibrosis.

Uterine fibroids (myomas or leiomyomas) are common benign tumors of reproductive aged women. Fibroids are clinically apparent in 20-50% of women, and cause abnormal uterine bleeding, abdominal pain an...

Drugging the Cancers Addicted to DNA Repair.

Defects in DNA repair can result in oncogenic genomic instability. Cancers occurring from DNA repair defects were once thought to be limited to rare inherited mutations (such as BRCA1 or 2). It now ap...

Nanocarriers as treatment modalities for hypertension.

Hypertension, a worldwide epidemic at present, is not a disease in itself rather it is an important risk factor for serious cardiovascular disorders including myocardial infarction, stroke, heart fail...

News Articles [6387 Associated News Articles listed on BioPortfolio]

Center Laboratories Inc 4123 Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryCenter Laboratories Inc Center Laboratories is a pharmaceutical company that develops, manufactures and markets oral medical solutions. The company's products include CNS drugs, analgesic drugs...

Anesthetic Effect Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01072017] Prices from USD $2000

DelveInsight's, Anesthetic Effect Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 report provides comprehensive insights about marketed and Phase III products for the Anestheti...

Inadequate T-cell development linked to autoimmune diseases

As part of their ongoing fundamental research program, scientists at the Monash Biomedicine Discovery Institute have built on previous research which had determined that the enzyme protein tyrosine ph...

STAT Plus: Lawmakers push drug makers to explain soaring prices for MS drugs

Two Democratic lawmakers are pressing major pharmaceutical companies to explain their pricing strategies for multiple sclerosis.

Multiple Sclerosis Drug Price Increases Probed By House Oversight Panel Democrats

Reps. Cummings and Welch contact seven manufacturers of multiple sclerosis drugs with inquiries about persistent and significant annual price increases...   

Chess Study Revives Debate over Cognitive-Enhancing Drugs

(JAMA) – While media attention has since waned, the underground use of CEs seemingly has not. A 2013 survey found that 19.9% of the 1105 German surgeons who responded admitted to having taken a ...

The Search for Vaccines against Street Drugs

(The Economist) – BETWEEN 2000 and 2015 half a million people in America alone died of drug overdoses—mostly of opioids, a class of addictive, generally synthetic painkillers related to morphi...

HER2 Antibodies Market to Reach US$ 21,669.1 Million by 2025; Perjeta and Other Promising Pipeline Drugs Augur well for Future

ALBANY, New York, August 17, 2017 /PRNewswire/ -- A recent market intelligence study by Transparency Market Research (TMR) suggests that the global HER2 antibodies market offers lucrative opportun...

Medullary Thyroid Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01072017] Prices from USD $2000

DelveInsight's, Medullary Thyroid Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 report provides comprehensive insights about marketed and Phase III products for the Me...

CVS Pharmacy gets URAC Community Pharmacy reaccreditation

David Salazarhe accreditation is the result of the CVS Pharmacy demonstrating a commitment to quality care, improved processes and better patient outcomes, and encompasses all CVS Pharmacy, Longs Drug...

Events [0 Results]

None

Companies [277 Associated Companies listed on BioPortfolio]

Context Therapeutics

Context Therapeutics is a private, Philadelphia, PA-based biotechnology company dedicated to creating new medicines to treat Sigma1-associated diseases. The company leverages brea...

Samumed, LLC

Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and in...

StemSynergy Therapeutics, Inc.

StemSynergy is a privately held biopharmaceutical company that focuses on the discovery and development of drugs targeting developmental pathways fundamental to cancer. For more i...

Repare Therapeutics Inc.

Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell b...

Modra Pharmaceuticals

Modra Pharmaceuticals is contributing to modern cancer treatment options by improving the delivery and bioavailability of chemotherapy, the backbone of oncology regimens today. Th...

Tanner Pharma Group

For over 15 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partn...

Abreos Biosciences

Abreos Biosciences is focused on ligand binding assays for biologic and biosimilar drug development, activity validation, authentication, and precision dosing, as well as massivel...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunocon...

Rare Disease Communications

Rare Disease Communications® is a healthcare communications and media company focused on the rare disease community and dedicated to raising awareness of rare diseases and orph...

Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna’s primary indication is acute ...

Clinical Trials [1311 Associated Clinical Trials listed on BioPortfolio]

Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients

Spontaneous recovery of patients infected with HCV is related to the development of a cytotoxic immune response that is executed by specialized white blood cells, the CD8+ T cells, which d...

Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation

Graft versus Host disease ( GVHD) is one of the major complications of Allogeneic Stem Cell Transplantation. Acute GVHD develops early ( within 2to 3 months) after transplantation and is t...

E-learning to Prevent Drug Errors in Anesthesia

The purpose of this observational study is to assess the efficiency of an e-learning in order to put into practice some preventive measures to avoid medication errors during anesthesia.

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients

This is phase II study. Efficacy and safety evaluation of IBI308 in patients with relapsed/refractory extranodal NK/T cell lymphoma, nasal type: a multicenter, single arm.

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

The proposed 3-week, double-blind, crossover, proof of concept study aims to manipulate neurochemical dysfunctions characteristic of individuals with co-occurring BD and AUD (i.e., abnorma...

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

The purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will ...

A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

This is a phase II single center, open-label, single arm study of palbociclib treatment in patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic chemot...

Special dr ug Use Surveillance of Takecab for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-stero

The purpose of this study is to investigate the safety and efficacy of long-term administration of Vonoprazan tablets (Takecab tablets) for up to 12 months in the routine clinical setting ...

This Trial Compares BI 695501 and Humira® in Patients With a Long-term Disease That Causes Red, Scaly Patches on the Skin (Plaque Psoriasis). The Trial Looks at the Way the Body Takes up the Drugs and How Effective and Safe They Are

The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with m...

Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients

It had been shown that high percentage of severe preeclampsia patients got a high cerebral perfusion pressure (CPP) due to abnormal autoregulation of cerebral blood vessels with associated...

Videos

None available.

Medical and Biotech [MESH] Definitions

A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity.

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.

The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.

Quick Search
Advertisement
 
review and buy Cytotoxic drugs market research data and corporate reports here

Channels Quicklinks